ACRP CPI Certified Principal Investigator

According to ICH E6, what is the primary responsibility of the Principal Investigator regarding the conduct of a clinical trial at the investigator site?

• AOverall accountability for the conduct of the trial at the site
• BRecruiting the maximum number of participants
• CEnsuring the sponsor's financial interests are protected
• DManaging the site's general business operations

Under ICH E6, when may a Principal Investigator delegate trial-related duties to a sub-investigator or other qualified team member?

• AOnly when the PI is on vacation or leave
• BWhen the delegate is qualified by education, training, and experience, and delegation is…
• CWhenever the PI determines the task is routine
• DOnly with prior written approval from the regulatory authority

What document serves as the primary reference for investigators regarding the clinical and nonclinical data of an investigational product?

• AThe study protocol
• BThe Investigator's Brochure
• CThe case report form
• DThe informed consent document

According to ICH E6, the informed consent process must include which of the following?

• AA guarantee that the investigational product will be effective
• BAdequate explanation of the trial and sufficient time for the participant to decide
• CA requirement that participants pass a written comprehension test
• DSignature from a family member in all cases

Which international ethical guideline, referenced by the ICH E6, establishes ethical principles for medical research involving human subjects?

• AThe Nuremberg Code
• BThe Declaration of Helsinki
• CThe Belmont Report
• DThe Common Rule

Per ICH E6, what is the role of the IRB/IEC in relation to a clinical trial?

• ATo recruit study participants on behalf of the investigator
• BTo safeguard the rights, safety, and well-being of trial subjects
• CTo manage the site budget and contract negotiations
• DTo conduct source data verification visits

A serious adverse event (SAE) is defined by ICH E6 as any untoward medical occurrence that at any dose results in which of the following?

• AAny adverse event that resolves within 24 hours
• BDeath, life-threatening event, hospitalization, disability, congenital anomaly, or other…
• COnly events directly caused by the investigational product
• DAny event requiring a protocol amendment

What is the purpose of the delegation of authority log in a clinical trial?

• ATo document all study participants enrolled
• BTo list all trial-related duties delegated by the PI and the individuals authorized to pe…
• CTo record the site's financial expenditures
• DTo track investigational product shipments

According to ICH E6, which of the following is considered an essential document that must be maintained at the investigator site?

• AThe sponsor's marketing plan
• BSigned informed consent forms for all participants
• CThe monitor's personal travel receipts
• DPress releases about the investigational product

What is the primary purpose of a study protocol in a clinical trial?

• ATo describe the objectives, design, methodology, statistical considerations, and organiza…
• BTo serve as the advertising material for participant recruitment
• CTo document the monitor's findings during site visits
• DTo provide financial projections for the trial

According to ICH E6, what must a PI do before enrolling the first participant in a clinical trial?

• APublish preliminary results in a peer-reviewed journal
• BObtain IRB/IEC approval for the protocol and informed consent form
• CComplete enrollment of all participants at other sites
• DSubmit a patent application for the investigational product

Which of the following best describes source data in the context of a clinical trial?

• AData entered into the electronic data capture system by the sponsor
• BAll information in original records and certified copies of original records used to reco…
• CSummary statistics generated after database lock
• DData published in the final study report

Per ICH E6, what should the investigator do if a protocol deviation occurs at the site?

• AIgnore it if it does not affect participant safety
• BDocument the deviation, report it to the sponsor and IRB/IEC, and implement corrective ac…
• CImmediately terminate the participant from the study
• DWait until the next monitoring visit to address it

What is the primary purpose of randomization in a clinical trial?

• ATo ensure every participant receives the investigational product
• BTo reduce bias by distributing known and unknown confounders equally among treatment grou…
• CTo allow the investigator to select which treatment each participant receives
• DTo ensure compliance with the informed consent process

According to ICH E6, the investigator must ensure adequate medical care for participants experiencing adverse events. Which of the following best reflects this obligation?

• AThe investigator should refer participants to the sponsor for all medical decisions
• BThe investigator should inform participants of adverse events relevant to their continued…
• CThe investigator should only address adverse events related to the investigational product
• DThe investigator's obligation ends when the participant completes the last study visit

What does GCP require regarding the qualifications of the investigator's staff performing trial-related procedures?

• AStaff must hold a doctoral degree
• BStaff must be qualified by education, training, and experience to perform their respectiv…
• CStaff must be employed full-time by the research institution
• DStaff qualifications are determined solely by the sponsor

Which ICH guideline specifically addresses the definitions and standards for expedited reporting of adverse drug reactions?

• AICH E6
• BICH E2A
• CICH E8
• DICH E9

What is the investigator's responsibility regarding investigational product accountability at the trial site?

• AThe investigator may delegate all IP accountability to the shipping department
• BThe investigator is responsible for IP accountability at the site, including receipt, sto…
• CIP accountability is solely the sponsor's responsibility
• DThe investigator only needs to track IP that has been dispensed to participants

A participant in a clinical trial wishes to withdraw consent. According to ICH E6, what must the investigator do?

• ARefuse the withdrawal until the study is completed
• BRespect the participant's decision and ensure no penalty or loss of benefits to which the…
• CReport the participant to the IRB/IEC for non-compliance
• DContinue all study procedures but stop collecting data

What is the primary purpose of a feasibility assessment before a site agrees to participate in a clinical trial?

• ATo determine the potential marketing value of the investigational product
• BTo evaluate whether the site has adequate resources, patient population, and infrastructu…
• CTo negotiate the highest possible per-patient payment
• DTo establish the site's publication rights

According to ICH E6, which of the following is true about the informed consent form (ICF)?

• AThe ICF may contain language that waives the participant's legal rights
• BThe ICF must be reviewed and approved by the IRB/IEC before use
• CThe ICF only needs to be signed at study completion
• DThe ICF does not need to mention potential risks

Per ICH E6, when the investigator becomes aware of an SAE, how quickly must it generally be reported to the sponsor?

• AWithin 30 days
• BImmediately, per the timelines specified in the protocol
• CAt the next scheduled monitoring visit
• DOnly if the IRB/IEC requests it

What is the correct action when a protocol amendment is approved by the sponsor?

• AImplement immediately before IRB/IEC review
• BObtain IRB/IEC approval before implementation, unless the change is necessary to eliminat…
• CImplement only after all participants have completed the current protocol version
• DWait for regulatory authority approval regardless of the nature of the change

A participant experiences a suspected unexpected serious adverse reaction (SUSAR). According to ICH E2A, what characterizes a SUSAR compared to an expected SAR?

• AA SUSAR is less severe than an expected SAR
• BA SUSAR is an adverse reaction that is both serious and not listed in the Investigator's…
• CA SUSAR only occurs in pediatric populations
• DA SUSAR is any adverse event that does not require hospitalization

An investigator discovers that a study team member has been performing procedures not listed on their delegation log. What is the most appropriate first action?

• ATerminate the team member immediately
• BUpdate the delegation log retroactively and document the finding with corrective action
• CReport the team member to law enforcement
• DIgnore the issue since the procedures were completed

During the informed consent process, a potential participant asks about alternative treatments available outside the study. According to ICH E6, the investigator should:

• ARefuse to discuss alternatives to avoid biasing the participant
• BExplain available alternative procedures or courses of treatment that may be beneficial
• CDirect the participant to research alternatives independently online
• DOnly discuss alternatives if the participant signs a separate waiver

An investigator is reviewing the Investigator's Brochure for a new study. Which section would contain information about the pharmacokinetic properties of the investigational drug?

• ASummary of clinical data
• BPhysical, chemical, and pharmaceutical properties
• CNonclinical studies — pharmacokinetics and product metabolism in animals
• DEffects in humans — pharmacokinetics and product metabolism

A PI is conducting a feasibility assessment for a new oncology trial. Which factor is MOST critical to evaluate?

• AThe distance between the site and the sponsor's headquarters
• BThe site's access to an adequate patient population meeting inclusion/exclusion criteria
• CThe number of publications the PI has authored
• DWhether the site has hosted social events for the sponsor before

Under ICH E6, when a significant new finding is discovered during the course of a trial that may affect participant safety or willingness to continue, the investigator must:

• AWait until the end of the study to inform participants
• BUpdate the informed consent form and re-consent participants as appropriate
• COnly inform participants who specifically ask about new findings
• DNotify participants verbally without updating the written consent

A sponsor-investigator is defined in ICH E6 as an individual who:

• AIs employed by the sponsor company to monitor the trial
• BBoth initiates and conducts a clinical trial, assuming both sponsor and investigator resp…
• CIs the principal investor in the pharmaceutical company
• DServes only as a consultant to the IRB/IEC

According to ICH E6, which of the following must be documented before the investigator begins enrolling participants?

• AThe investigator's personal financial tax returns
• BEvidence that the site has adequate resources, including qualified staff and appropriate…
• CA signed agreement that the investigator will purchase the sponsor's products after the t…
• DCertification that the investigator has completed a marketing course

In terms of investigational product management, what temperature monitoring requirement does GCP establish for IP storage?

• ARoom temperature is always acceptable for all investigational products
• BStorage conditions must be maintained as specified by the sponsor, and monitoring must be…
• CTemperature monitoring is only required for biological products
• DThe monitor is solely responsible for temperature documentation

A clinical trial requires unblinding for a participant who presents to the emergency department with a suspected serious adverse reaction. Who has the authority to unblind the treatment assignment?

• AOnly the sponsor's medical monitor
• BThe investigator, if the protocol provides for emergency unblinding and it is necessary f…
• CAny member of the emergency department staff
• DThe participant themselves using a patient portal

When reviewing a protocol, the investigator notes that the exclusion criteria include 'participation in another clinical trial within the past 30 days.' What is the primary reason for this washout period?

• ATo prevent participants from earning payments from multiple studies simultaneously
• BTo minimize the risk of carryover effects from prior investigational products and ensure…
• CTo comply with the site's scheduling limitations
• DTo reduce the sponsor's administrative burden

According to ICH E2A, a fatal or life-threatening SUSAR occurring in a clinical trial must be reported to regulatory authorities within what timeframe?

• A30 calendar days
• B15 calendar days
• C7 calendar days, with a follow-up within 8 additional days
• D90 calendar days

An investigator receives an annual IND safety report from the sponsor. What information does this report typically contain?

• AA summary of the site's financial performance
• BA comprehensive analysis of all safety information accumulated during the reporting perio…
• COnly the individual SAE case reports from the investigator's own site
• DThe sponsor's marketing forecasts for the investigational product

Per ICH E6, the investigator must provide the IRB/IEC with which of the following as part of ongoing trial oversight?

• AAnnual progress reports on the trial's status
• BOnly the final study report at trial conclusion
• CMonthly financial statements
• DThe monitor's personal assessment of the PI's competence

An investigator identifies a conflict of interest related to a clinical trial they are conducting. According to GCP principles, what is the appropriate course of action?

• AKeep the conflict private to avoid undermining confidence in the trial
• BDisclose the conflict to the sponsor, IRB/IEC, and institution as required by applicable…
• CWithdraw from the trial without informing anyone
• DOnly disclose the conflict if it exceeds a monetary threshold set by the investigator

A monitor conducting source data verification discovers a discrepancy between a participant's medical record and the CRF entry for a lab value. What should the investigator do?

• ADelete the CRF entry and re-enter the correct value without documentation
• BReview the discrepancy, correct the CRF entry with proper documentation (reason for chang…
• CInstruct the monitor to correct the CRF themselves
• DLeave the discrepancy unresolved until the end of the study

According to ICH E6, how long must the investigator retain essential trial documents after the completion or discontinuation of a trial?

• A1 year
• BUntil the sponsor notifies the investigator that records are no longer needed, in accorda…
• C6 months after database lock
• DOnly until the final study report is published

During a clinical trial, a participant reports a new symptom. The investigator determines it is a non-serious adverse event. According to ICH E6, what documentation is required?

• ANo documentation is needed for non-serious adverse events
• BThe adverse event must be recorded, including onset, severity, duration, relationship to…
• COnly a verbal note in the daily study log
• DDocumentation is only needed if the participant specifically requests it

Which of the following is a key component of ICH E8 (General Considerations for Clinical Trials)?

• ADetailed instructions for manufacturing the investigational product
• BThe concept of quality by design, emphasizing that clinical trials should focus on questi…
• CSpecific statistical formulas for sample size calculation
• DMarketing authorization requirements for approved products

What is the primary function of a Data Safety Monitoring Board (DSMB) in a clinical trial?

• ATo manage the site's data entry processes
• BTo independently review accumulating trial data and recommend whether to continue, modify…
• CTo serve as the primary IRB/IEC for the trial
• DTo audit the sponsor's financial records

An investigator is preparing for a regulatory inspection. Which of the following should be readily available for the inspector?

• AOnly the case report forms
• BAll essential documents including the protocol, IRB/IEC correspondence, signed ICFs, IP a…
• COnly the final study report
• DOnly the financial records of the trial

When the PI receives a safety notification from the sponsor about a newly identified risk associated with the investigational product, what actions should be taken?

• AFile the notification without further action
• BReview the notification, assess the impact on current participants, update the IRB/IEC, c…
• CStop the trial immediately without consulting the sponsor
• DOnly review it at the next scheduled team meeting

An investigator-sponsor agreement typically includes all of the following EXCEPT:

• AThe investigator's commitment to conduct the trial per GCP and protocol
• BThe investigator's obligation to allow monitoring and auditing access
• CA guarantee that the investigational product will receive marketing approval
• DProvisions for IP handling and accountability